艾曲波帕在血小板减少中的应用进展  

Clinical Application of Eltrombopag in Patients with Thrombocytopenia

作　　者：张岩[1] 付玥玥 李丽敏[1] 周晋[1] ZHANG Yan;FU Yueyue;LI Limin;ZHOU Jin(Department of Hematology,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院血液内科,哈尔滨150001

出　　处：《医学综述》2020年第21期4268-4272,共5页Medical Recapitulate

摘　　要：血小板减少是多种血液疾病的共同表现,患者生活质量差,出血风险高,已成为重要的临床问题之一。尽管血小板减少的治疗取得了一定进展,但血小板减少患者的治疗效果欠佳,仍需要寻找新的治疗策略。血小板生成素(TPO)作为影响血小板生成的重要细胞因子与TPO受体结合激活巨核细胞产生血小板,艾曲波帕是一种苯丙咔唑类化合物,与TPO功能相似可促进血小板产生,用于治疗慢性特发性血小板减少性紫癜、再生障碍性贫血、慢性丙型病毒性肝炎导致的血小板减少疗效显著。因其口服方便、安全有效逐渐扩大治疗范围,成为研究热点。Thrombocytopenia is a common manifestation of many diseases,with poor quality of life and high risk of bleeding of the patients,and has become one of the important clinical problems.Although some progress has been made in the treatment of thrombocytopenia,the therapeutic effect is not satisfactory,and new treatment strategies still need to be found.Thrombopoietin(TPO),an important cytokine that affects platelet production,binds to TPO receptors and activates megakaryocytes to produce platelets.Eltrombopag is a phenprocarbazole compound that functions similarly to TPO and can promote platelet production,and has shown significant effect in the treatment of chronic idiopathic thrombocytopenic purpura,aplastic anemia,and chronic hepatitis C virus-induced thrombocytopenia.Due to its convenient oral administration,good safety and effect,its therapeutic application has been gradually expanding,and has become a research hotspot.

关 键 词：特发性血小板减少性紫癜 血小板减少 艾曲波帕 

分 类 号：R551.3[医药卫生—血液循环系统疾病] R457.7[医药卫生—内科学]